Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

No serious adverse events were reported. Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic ...

Results in vitiligo came from the TRuE-V1 and TRuE-V2 studies, which showed that around 30% of patients treated with ruxolitinib cream twice daily achieved 75% or more improvement from baseline in ...

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis.

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura (ruxolitinib) cream recorded.Incyte estimates Jakafi net income for 2025 is ...